The companies will pair sequencing with genotype-phenotype matching and analytics in pursuit of wider access to precision medicine and faster, more accurate diagnoses.
The new funding brings the Series B total to £23.3 million for the British clinical decision support technology developer.
The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.
Farsight Genome Systems is touting the rapid scalability of its analytic pipeline as it seeks to make its technology "future-proof" for clinical genomics labs.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.